EU/3/10/726: Orphan designation for the treatment of Gaucher disease

Taliglucerase alfa

Table of contents


On 23 March 2010, orphan designation (EU/3/10/726) was granted by the European Commission to Protalix B.V., the Netherlands, for taliglucerase alfa for the treatment of Gaucher disease.

The sponsorship was transferred to Pfizer Limited, United Kingdom, in September 2010 and subsequently to Pfizer Europe MA EEIG, Belgium, in November 2018.

Key facts

Active substance
Taliglucerase alfa
Intended use
Treatment of Gaucher disease
Orphan designation status
EU designation number
Date of designation

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Brussels-Capital Region

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating